A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06961370 on ClinicalTrials.gov Phase 1 Hoffmann-La Roche (industry) Started 2025-07-16 Terminated

Riskier than 50% of active trials

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Terminated on 2026-03-03, after 2025-07-16 start.

Reason given by the sponsor: “safety”

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-03-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tolerabilitypresence ofeyepdamd
Phrases that lowered it: participants20diabeticinvestigateopen label
Accepts healthy volunteers: No (raises risk) · Who can join
Sponsor's past termination rate: 11.9% (raises risk) · Sponsor's track record
Sponsor's past trials: 1403 (raises risk) · Sponsor's track record
Phase: 1 (lowers risk) · Design
Minimum age: 55 (raises risk) · Who can join
Drug's FAERS reports with a death: 5.5% (lowers risk) · Drug's FDA history
Design: parallel (raises risk) · Design
Drug's FAERS reports marked serious: 63.5% (lowers risk) · Drug's FDA history
Trials the sponsor started in the prior 2 years: 60 (lowers risk) · Sponsor's track record
Disease area, cancer: No (lowers risk) · Disease area
Has a data monitoring committee: No (lowers risk) · Design
Blinding: triple (raises risk) · Design
Sponsor type: industry (lowers risk) · Sponsor's track record
Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1 (typical: 2)
Number of arms: 3 (typical: 2)
Allocation: randomized
Design: parallel
Primary purpose: treatment
Blinding: triple (typical: none)
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: sponsor
Collaborators: 0
Keywords listed: 0 (typical: 1)

Who can join

Minimum age: 55 (typical: 18)
Maximum age: not given (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 1403 (typical: 32)
Sponsor's past termination rate: 11.9% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 60 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 2 (typical: 1)
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 1500 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 667 (typical: 412.5)
Drug's FAERS reports marked serious: 63.5% (typical: 85.6%)
Drug's FAERS reports with a death: 5.5% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: avacincaptad pegol, pegcetacoplan

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) NCT03295877 · started 2017 · scored riskier than 29% of active trials completed
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT04615325 · started 2020 · scored riskier than 47% of active trials completed
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) NCT02484690 · started 2015 · scored riskier than 37% of active trials completed
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration NCT01941082 · started 2013 · scored riskier than 30% of active trials completed
Safety and Efficacy of AM712 in Patients with NAMD NCT05345769 · started 2022 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.